American non-profit health policy group
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Insurers are signaling double‑digit premium increases for 2027 in preliminary rate filings across 16 states and the District of Columbia. Analysts attribute the rise to higher healthcare costs and the expiration of pandemic‑era subsidies, with enrollment shrinking as affordability pressures mount.